beta

ALPN

Alpine Immune Sciences Inc.

Alpn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-08-2018 08-09-2018 05-14-2018 03-28-2018 11-13-2017 07-21-2017 05-09-2017
Actual EPS -0.88 -0.57 -0.38 -0.33 -0.19 -0.72 -1.4
Consensus EPS -0.57 -0.44 -0.42 -0.44 -0.62 -0.96 -1.92
Estimated EPS -0.57 -0.44 -0.42 -0.44 -0.62 -0.96 -1.92
Number of Estimates 4 2 1 1 1 3 2
EPS Surprise -$0.31 -$0.13 $0.04 $0.11 $0.43 $0.24 $0.52

Stats

Summary

Nivalis Therapeutics Inc a pharmaceutical company, focuses on the discovery and development of product candidates for patients with cystic fibrosis. Geographically operation of the group is functioned through United States.

Market Cap: 161 Million

Primary Exchange: NASDAQ Global Market

Website: https://www.alpineimmunesciences.com

Shares Outstanding: 13.9 Million

Float: 13.7 Million

Dividend: 0.0 (0.0%)

Beta: 0.24637

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 31.6 Thousand

Ethical Flags

Animal testing

Longest drawdown: 823 trading days

From: 2015-08-21 To: 2018-12-07

Lowest Point:

Alpine Immune Sciences Showcases Key Preclinical Data at 60th American Society of Hematology Annual Meeting and Exposition

via: Business Wire at 2018-12-03 07:00:00:000

Companys Lead Program, ALPN-101, Demonstrates Activity in Animal Models of Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Alpine Also Highlights Potential for Transmembrane and Secreted Immunomodulatory Proteins to Enhance Activity of Engineered T Cells … read more...

Alpine Immune Sciences Showcases Key Preclinical Data at 60th American Society of Hematology Annual Meeting and Exposition

via: Business Wire at 2018-12-03 07:00:00:000

Companys Lead Program, ALPN-101, Demonstrates Activity in Animal Models of Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Alpine Also Highlights Potential for Transmembrane and Secreted Immunomodulatory Proteins to Enhance Activity of Engineered T Cells … read more...

Alpine Immune Sciences Showcases Key Preclinical Data at 60th American Society of Hematology Annual Meeting and Exposition

via: Business Wire at 2018-12-03 07:00:00:000

Companys Lead Program, ALPN-101, Demonstrates Activity in Animal Models of Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Alpine Also Highlights Potential for Transmembrane and Secreted Immunomodulatory Proteins to Enhance Activity of Engineered T Cells … read more...

Alpine Immune Sciences Announces ALPN-101 Data to be Included in Oral Presentation at 60th American Society of Hematology Annual Meeting and Exposition

via: Business Wire at 2018-11-29 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced pre-clinical data from its lead autoimmune/inflammatory program, ALPN-101, will be included in an o… read more...

Alpine Immune Sciences Announces ALPN-101 Data to be Included in Oral Presentation at 60th American Society of Hematology Annual Meeting and Exposition

via: Business Wire at 2018-11-29 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced pre-clinical data from its lead autoimmune/inflammatory program, ALPN-101, will be included in an o… read more...

Alpine Immune Sciences Announces ALPN-101 Data to be Included in Oral Presentation at 60th American Society of Hematology Annual Meeting and Exposition

via: Business Wire at 2018-11-29 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced pre-clinical data from its lead autoimmune/inflammatory program, ALPN-101, will be included in an o… read more...

Ziopharm: Elucidating The Regeneron Partnership For Glioblastoma

via: SeekingAlpha at 2018-11-14 10:55:00:000

We have to do what I would call anomalies: we have to look for strange things that show up once in a while. They don't show up all the time. We have to be scanning the horizon, and doing that, once in a while something will show up that makes a lot of sense, and then you act on it. - The Dhan… read more...

Ziopharm: Elucidating The Regeneron Partnership For Glioblastoma

via: SeekingAlpha at 2018-11-14 10:55:00:000

We have to do what I would call anomalies: we have to look for strange things that show up once in a while. They don't show up all the time. We have to be scanning the horizon, and doing that, once in a while something will show up that makes a lot of sense, and then you act on it. - The Dhan… read more...

Ziopharm: Elucidating The Regeneron Partnership For Glioblastoma

via: SeekingAlpha at 2018-11-14 10:55:00:000

We have to do what I would call anomalies: we have to look for strange things that show up once in a while. They don't show up all the time. We have to be scanning the horizon, and doing that, once in a while something will show up that makes a lot of sense, and then you act on it. - The Dhan… read more...

Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board

via: Business Wire at 2018-11-09 08:00:00:000

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancers (SITC) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders … read more...

Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board

via: Business Wire at 2018-11-09 08:00:00:000

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancers (SITC) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders … read more...

Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board

via: Business Wire at 2018-11-09 08:00:00:000

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancers (SITC) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders … read more...

Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board

via: Business Wire at 2018-11-09 08:00:00:000

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancers (SITC) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders … read more...

Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board

via: Business Wire at 2018-11-09 08:00:00:000

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancers (SITC) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders … read more...

Alpine Immune Sciences misses by $0.31

via: SeekingAlpha at 2018-11-08 17:05:05:000

Alpine Immune Sciences (NASDAQ: ALPN ): Q3 GAAP EPS of -$0.88 misses by $0.31. More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results

via: Business Wire at 2018-11-08 16:35:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter ended September30, 2018. &… read more...

Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

via: Business Wire at 2018-11-05 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in November. The company will… read more...

Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

via: Business Wire at 2018-11-05 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in November. The company will… read more...

Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

via: Business Wire at 2018-11-05 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in November. The company will… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Alpine Immune Sciences Announces Scientific Presentations at 60th American Society of Hematology Annual Meeting and Exposition

via: Business Wire at 2018-11-01 11:14:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the 60 th American Society of Hematology (ASH) Annual Meeting… read more...

Alpine Immune Sciences' Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation

via: Business Wire at 2018-10-22 07:00:00:000

Data from experimental models of inflammatory arthritis and multiple sclerosis presented at 2018 ACR/ARHP Annual Meeting and 143 rd Annual Meeting of the American Neurological Association ALPN-101 has completed CMC scale up and is poised to be the first dual ICOS/CD28 antag… read more...

Alpine Immune Sciences' Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation

via: Business Wire at 2018-10-22 07:00:00:000

Data from experimental models of inflammatory arthritis and multiple sclerosis presented at 2018 ACR/ARHP Annual Meeting and 143 rd Annual Meeting of the American Neurological Association ALPN-101 has completed CMC scale up and is poised to be the first dual ICOS/CD28 antag… read more...

Alpine Immune Sciences' Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation

via: Business Wire at 2018-10-22 07:00:00:000

Data from experimental models of inflammatory arthritis and multiple sclerosis presented at 2018 ACR/ARHP Annual Meeting and 143 rd Annual Meeting of the American Neurological Association ALPN-101 has completed CMC scale up and is poised to be the first dual ICOS/CD28 antag… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-19 11:08:18:000

Noteworthy events during the week of October 21 - 27 for healthcare investors. More news on: Alpine Immune Sciences, Inc., NovoCure, ViewRay, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-19 11:08:18:000

Noteworthy events during the week of October 21 - 27 for healthcare investors. More news on: Alpine Immune Sciences, Inc., NovoCure, ViewRay, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-19 11:08:18:000

Noteworthy events during the week of October 21 - 27 for healthcare investors. More news on: Alpine Immune Sciences, Inc., NovoCure, ViewRay, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-12 08:52:08:000

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-12 08:52:08:000

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-12 08:52:08:000

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-12 08:52:08:000

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-12 08:52:08:000

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more … read more...

Alpine Immune Sciences: Digging Into A Recent Newcomer Onto The Immunotherapy Scene

via: SeekingAlpha at 2018-10-11 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy is easily one of… read more...

Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting

via: Business Wire at 2018-10-04 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 33 rd Annual M… read more...

Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting

via: Business Wire at 2018-10-04 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 33 rd Annual M… read more...

Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting

via: Business Wire at 2018-10-04 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 33 rd Annual M… read more...

Alpine Immune Sciences to Present at Ladenburg Thalmann 2018 Healthcare Conference

via: Business Wire at 2018-09-25 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 at… read more...

Alpine Immune Sciences to Present at Ladenburg Thalmann 2018 Healthcare Conference

via: Business Wire at 2018-09-25 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 at… read more...

Alpine Immune Sciences to Present at Ladenburg Thalmann 2018 Healthcare Conference

via: Business Wire at 2018-09-25 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 at… read more...

Alpine Immune Sciences Announces Upcoming Scientific Presentations

via: Business Wire at 2018-09-24 07:00:00:000

ALPN-101 preclinical data to be presented at the 2018 ACR/ARHP Annual Meeting and the 143 rd Annual Meeting of the American Neurological Association Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for c… read more...

Alpine Immune Sciences misses by $0.14, beats on revenue

via: SeekingAlpha at 2018-08-09 16:36:17:000

Alpine Immune Sciences (NASDAQ: ALPN ): Q2 EPS of -$0.57 misses by $0.14 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Alpine Immune Sciences misses by $0.14, beats on revenue

via: SeekingAlpha at 2018-08-09 16:36:17:000

Alpine Immune Sciences (NASDAQ: ALPN ): Q2 EPS of -$0.57 misses by $0.14 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Alpine Immune Sciences misses by $0.14, beats on revenue

via: SeekingAlpha at 2018-08-09 16:36:17:000

Alpine Immune Sciences (NASDAQ: ALPN ): Q2 EPS of -$0.57 misses by $0.14 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial Results

via: Business Wire at 2018-08-09 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the … read more...

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial Results

via: Business Wire at 2018-08-09 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the … read more...

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial Results

via: Business Wire at 2018-08-09 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the … read more...

Alpine Immune Sciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

via: Business Wire at 2018-08-08 18:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today reported the grant of an equity inducement award to Mark Litton, Ph.D., Alpines new President and … read more...

Alpine Immune Sciences to Present at 2018 Wedbush PacGrow Healthcare Conference

via: Business Wire at 2018-08-06 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at the 2018 Wedbush PacGrow Healthcare … read more...

Alpine Immune Sciences to Present at 2018 Wedbush PacGrow Healthcare Conference

via: Business Wire at 2018-08-06 16:05:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at the 2018 Wedbush PacGrow Healthcare … read more...

Alpine Immune Sciences Strengthens Leadership Team with Appointment of Mark Litton as President and Chief Operating Officer

via: Business Wire at 2018-08-06 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today announced the appointment of life sciences veteran Mark Litton, Ph.D. to the role of President and Chief O… read more...

Alpine Immune Sciences Strengthens Leadership Team with Appointment of Mark Litton as President and Chief Operating Officer

via: Business Wire at 2018-08-06 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today announced the appointment of life sciences veteran Mark Litton, Ph.D. to the role of President and Chief O… read more...

Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital

via: Business Wire at 2018-07-20 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zheji… read more...

Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital

via: Business Wire at 2018-07-20 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zheji… read more...

Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital

via: Business Wire at 2018-07-20 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zheji… read more...

Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital

via: Business Wire at 2018-07-20 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zheji… read more...

Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital

via: Business Wire at 2018-07-20 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zheji… read more...

Rounds Report: Alpine Immune Sciences Broke The Trend In A Down Market

via: SeekingAlpha at 2018-07-18 05:04:46:000

A change in net income, a change in a companys management, appearance of a new invention or a new discovery, a change in interest rates or tax laws - these are but a few random examples of conditions that will bring about a rise or fall in the quotes for a particular common stock. All… read more...

Rounds Report: Alpine Immune Sciences Broke The Trend In A Down Market

via: SeekingAlpha at 2018-07-18 05:04:46:000

A change in net income, a change in a companys management, appearance of a new invention or a new discovery, a change in interest rates or tax laws - these are but a few random examples of conditions that will bring about a rise or fall in the quotes for a particular common stock. All… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

via: SeekingAlpha at 2018-06-07 17:22:23:000

Without a saving faith in the future, no one would ever invest at all. To be an investor, you must be a believer in a better tomorrow. - Benjamin Graham In a Seeking Alpha interview back on Sep. 23, 2017, the ingenious market strategist (Robyn Conti) inquired, "What's one idea you feel s… read more...

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

via: SeekingAlpha at 2018-06-07 17:22:23:000

Without a saving faith in the future, no one would ever invest at all. To be an investor, you must be a believer in a better tomorrow. - Benjamin Graham In a Seeking Alpha interview back on Sep. 23, 2017, the ingenious market strategist (Robyn Conti) inquired, "What's one idea you feel s… read more...

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

via: SeekingAlpha at 2018-06-07 17:22:23:000

Without a saving faith in the future, no one would ever invest at all. To be an investor, you must be a believer in a better tomorrow. - Benjamin Graham In a Seeking Alpha interview back on Sep. 23, 2017, the ingenious market strategist (Robyn Conti) inquired, "What's one idea you feel s… read more...

Integrated BioSci Investing Research: Portfolio Management And Investment Strategy

via: SeekingAlpha at 2018-06-07 06:50:44:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stampeded o… read more...

Integrated BioSci Investing Research: Portfolio Management And Investment Strategy

via: SeekingAlpha at 2018-06-07 06:50:44:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stampeded o… read more...

Integrated BioSci Investing Research: Portfolio Management And Investment Strategy

via: SeekingAlpha at 2018-06-07 06:50:44:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stampeded o… read more...

Alpine Immune Sciences to Present at Jefferies 2018 Global Healthcare Conference

via: Business Wire at 2018-05-22 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Jefferies 2018 Glob… read more...

Rounds Report: Alpine Rallies; Eleven BioTherapeutics Becomes Sesen Bio

via: SeekingAlpha at 2018-05-20 21:00:37:000

In the short run, the market is a voting machine, but in the long run, it is a weighing machine. Benjamin Graham Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 18, 2018. As usual, well elucidate notable trading analytics for the day… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-18 08:57:57:000

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Overweight rating and $60 (100% upside) price target at Piper Jaffray. More news on: Aimmune Therapeutics, Alpine Immune Sciences, Inc., Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Alpine Immune Sciences beats by $0.02

via: SeekingAlpha at 2018-05-14 16:31:03:000

Alpine Immune Sciences (NASDAQ: ALPN ): Q1 EPS of -$0.38 beats by $0.02 . Cash, cash equivalents, and short-term investments of $76.7M Press Release More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , read more...

Alpine Immune Sciences beats by $0.02

via: SeekingAlpha at 2018-05-14 16:31:03:000

Alpine Immune Sciences (NASDAQ: ALPN ): Q1 EPS of -$0.38 beats by $0.02 . Cash, cash equivalents, and short-term investments of $76.7M Press Release More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , read more...

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results

via: Business Wire at 2018-05-14 16:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the … read more...

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results

via: Business Wire at 2018-05-14 16:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the … read more...

Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

via: SeekingAlpha at 2018-05-11 02:25:51:000

A great business at a fair price is superior to a fair business at a great price. - Charlie Munger Alpine Immune Sciences (NASDAQ: ALPN ) is a highly promising grower that we recently featured in the prior research. Despite its nascent history, the company owns two highly valuable ther… read more...

Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

via: SeekingAlpha at 2018-05-11 02:25:51:000

A great business at a fair price is superior to a fair business at a great price. - Charlie Munger Alpine Immune Sciences (NASDAQ: ALPN ) is a highly promising grower that we recently featured in the prior research. Despite its nascent history, the company owns two highly valuable ther… read more...

Alpine: Explicating The Upcoming Catalysts Powering Robust Potential For This Stock

via: SeekingAlpha at 2018-05-10 03:07:37:000

Instead of looking for success, make a list of how to fail instead. Tell me where Im going to die, that is, so I dont go there. - Charlie Munger At Integrated BioSci Investing , we rarely feature coverage on a small firm unless its prospects are gargantuan. In breaking o… read more...

Alpine: Explicating The Upcoming Catalysts Powering Robust Potential For This Stock

via: SeekingAlpha at 2018-05-10 03:07:37:000

Instead of looking for success, make a list of how to fail instead. Tell me where Im going to die, that is, so I dont go there. - Charlie Munger At Integrated BioSci Investing , we rarely feature coverage on a small firm unless its prospects are gargantuan. In breaking o… read more...

Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors

via: Business Wire at 2018-04-24 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an experienced life sciences executive, currently serves as the Chief Executive Officer of Flashlight Therapeutics. We are pleased to have Chris join Al… read more...

Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors

via: Business Wire at 2018-04-24 07:00:00:000

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an experienced life sciences executive, currently serves as the Chief Executive Officer of Flashlight Therapeutics. We are pleased to have Chris join Al… read more...

Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model

via: Business Wire at 2018-04-17 14:00:00:000

-- ALPN-202 is a potential novel immuno-oncology therapy providing dual PD-L1/CTLA-4 antagonism with CD28 costimulation -- -- Unique mechanism seeks to address lack of costimulatory activity of existing immuno-oncology therapies -- -- Data Presented at 2018 American Association fo… read more...

Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model

via: Business Wire at 2018-04-17 14:00:00:000

-- ALPN-202 is a potential novel immuno-oncology therapy providing dual PD-L1/CTLA-4 antagonism with CD28 costimulation -- -- Unique mechanism seeks to address lack of costimulatory activity of existing immuno-oncology therapies -- -- Data Presented at 2018 American Association fo… read more...

Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators

via: SeekingAlpha at 2018-04-13 00:14:18:000

Dont be afraid of buying on a war scare. Through the entire twentieth century, with a single exception, every time major war has broken out anywhere in the world or whenever American forces have become involved in any fighting, whatever, the American stock market has always plunged s… read more...

Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators

via: SeekingAlpha at 2018-04-13 00:14:18:000

Dont be afraid of buying on a war scare. Through the entire twentieth century, with a single exception, every time major war has broken out anywhere in the world or whenever American forces have become involved in any fighting, whatever, the American stock market has always plunged s… read more...

An Integrated BioSci Report On Alpine Immune Sciences: A Stellar Next-Generation Immunotherapy Innovator

via: SeekingAlpha at 2018-04-01 03:18:36:000

We select such investments on a long-term basis, weighing the same factors as would be involved in the purchase of 100% of an operating business: (1) favorable long-term economic characteristics; (2) competent and honest management; (3) purchase price attractive when measured against t… read more...

Alpine Immune Sciences reports FY results

via: SeekingAlpha at 2018-03-28 07:06:17:000

Alpine Immune Sciences (NASDAQ: ALPN ): FY EPS of -$1.20 More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial Results

via: Business Wire at 2018-03-28 07:00:00:000

New preclinical data on ALPN-202 program to be presented at 2018 American Association for Cancer Research Annual Meeting Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse t… read more...

4th-Quarter 2017 Portfolio Review And Price Increase For Integrated BioScI Investing

via: SeekingAlpha at 2018-01-11 03:31:55:000

The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious. - The Father … read more...

What The Cell Design Labs Acquisition Means For Gilead?

via: SeekingAlpha at 2017-12-18 11:53:03:000

Trading Analytics And Recent News After going ex-dividend on Dec. 14, 2017, the share price of Gilead Sciences (NASDAQ: GILD ) took a temporarily dip, then bounced back above $75.57. Moreover, the stock is showing signs of rebounding once it receded significantly following the robust rise … read more...

Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease

via: Business Wire at 2017-12-09 07:30:00:000

-- Data Presented at 59 th American Society of Hematology Annual Meeting & Exposition -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results from … read more...

Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells

via: Business Wire at 2017-12-06 07:00:00:000

-- Data Presented at 2017 San Antonio Breast Cancer Symposium -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results of a preclinical study of novel immuno… read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-12-04 17:37:25:000

Top gainers: ALPN +4.7% . DEPO +4.1% . NAT +2.8% . IMMU +2.2% . XENE +2.1% . More news on: Alpine Immune Sciences, Inc., Depomed Inc., Nordic American Tankers Limited, Stocks on the move, Read more … read more...

How To Make Money With Gilead?

via: SeekingAlpha at 2017-11-16 05:32:09:000

Despite stellar developments with the historic approval of CAR-T, the share price of Gilead Sciences (NASDAQ: GILD ), a growth company (focusing on the innovation and commercialization of drugs to treat infectious diseases and cancers), continue to head South (after a temporary period of run… read more...

Alpine Immune Sciences reports Q3 results

via: SeekingAlpha at 2017-11-13 16:35:17:000

Alpine Immune Sciences (NASDAQ: ALPN ): Q3 EPS of $0.20 Revenue of $0.13M. Cash and equivalents $87.2M. Press Release More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , read more...

Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results

via: Business Wire at 2017-11-13 16:05:00:000

New preclinical data to be presented at multiple upcoming scientific meetings Strong balance sheet with $87.2 million in cash, cash equivalents, and short-term investments Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading immunotherapy company focused on developing t… read more...

Integrated BioSci Research On Gilead Sciences: Hitting The Next Growth Spurt With CAR-TCR And TIP-VIgD

via: SeekingAlpha at 2017-11-12 02:48:30:000

There is a tide in the affairs of men. Which, taken at the flood, leads on to fortune. - Brutus in Julius Caesar In the past months, shares of Gilead Sciences (NASDAQ: GILD ), a growth company (focusing on the innovation and commercialization of drugs to treat infectious … read more...

Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer's 32nd Annual Meeting

via: Business Wire at 2017-11-10 07:00:00:000

-- Companys vIgD Platform Well Positioned to Realize Next Generation Immuno-Oncology Therapeutics -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced immu… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2017-07-25 4.0 1.0 4.0
Data provided for free by IEX